Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...

Detailed price information for Slam Exploration Inc (SXL-X) from The Globe and Mail including charting and trades.

BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM ...

Air-polluting microplastics have been found in rural environments in greater quantities than in urban locations, researchers ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

In late 2025, the Company announced signing of an option agreement with Daura Gold on the Cerro Bayo and La Flora projects in Argentina. The agreed terms include up to US$1.7 million payable to Latin ...

Following an unusually warm pattern over the last week or so, residents across the East will observe a return of winter ...

New data from the James Webb Space Telescope supports the existence of a supermassive black hole moving at 2.2 million mph, leaving behind a trail of stars and gas, researchers report.

Polymer-coated cotton fabric generates electricity from ambient humidity day and night, powering LEDs for over 24 hours and ...

Researchers from the Department of Energy's SLAC National Accelerator Laboratory and the University of California, Los ...

Cells do more than carry out chemical reactions. New theoretical work suggests they may also generate usable electrical ...

In 2025, AI took investors on a date. In 2026, the nascent technology may need to start footing the bill. This maturation ...